Abstract:You have accessJournal of UrologyBladder Cancer: Non-invasive III (PD48)1 May 2024PD48-06 URINE CELLULAR DNA METHYLATION AND MUTATION TEST FOR DETECTING UROTHELIAL CARCINOMA Yucai Wu, Yanqing Gong, Shiming He, Liqun Zhou, and Xuesong Li Yucai WuYucai Wu , Yanqing GongYanqing Gong , Shiming HeShiming He , Liqun ZhouLiqun Zhou , and Xuesong LiXuesong Li View All Author Informationhttps://doi.org/10.1097/01.JU.0001008712.53259.7d.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The preoperative qualitative diagnosis of urothelial carcinoma (UC) is a clinical focus and challenge. Currently, non-invasive urine diagnostic technologies are difficult to provide sufficient evidence and meet clinical needs. The purpose of this study is validating the diagnostic performance of the optimal marker panel (novel methylation marker NRN1 plus TERT [C228T] and FGFR3 [p. S249C] mutation) in a prospective, blinded and multicenter clinical trial. METHODS: From March 2022 to January 2023, 164 UC patients, 30 other urological tumor patients and 192 benign disease patients were prospectively enrolled at three centers from China. Using urine cellular DNA point mutation and methylation diagnostic technology developed earlier by qPCR, these patients were assessed for disease and their sensitivity, specificity, and accuracy were calculated. The diagnostic performance of this technology was compared with the commonly used urine cytology and FISH in clinical practice, and validated for recurrence monitoring in a surveillance cohort (n=18) (Figure 1). RESULTS: The DNA methylation rate of UC patients was significantly higher than that of benign patients and other urological tumor patients. Based on the UC diagnostic panel of a methylation marker NRN1 plus TERT and FGFR3 mutation, it had high diagnostic accuracy (91.6%), sensitivity (92.1%), and specificity (91.1%) for UC patients, significantly higher in sensitivity than urine cytology (35.1%) and FISH (57.1%). The sensitivity of this panel in early-stage, low-grade and recurrent patients also reached 90.6%, 81.0% and 85.7%, respectively. When combined with the age parameter to assist diagnosis, the model was optimized, and the AUC value reached 0.935 (Figure 2). CONCLUSIONS: The UC diagnostic model based on the methylation marker NRN1 plus TERT (C228T) and FGFR3 (p. S249C) mutation is a rapid (1-2 days), non-invasive, and highly robust method for UC. Combined with imaging localization diagnosis, it is expected to reduce the number of preoperative endoscopy examinations and improve diagnosis efficiency. Download PPTDownload PPT Source of Funding: This research is supported by grants from the National Natural Science Foundation of China (No. 82273350 and 81872083), the Natural Science Foundation of Beijing (No. 7222190) and the Beijing Municipal Science & Technology Commission Project (No. Z201100005420029) © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e989 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Yucai Wu More articles by this author Yanqing Gong More articles by this author Shiming He More articles by this author Liqun Zhou More articles by this author Xuesong Li More articles by this author Expand All Advertisement PDF downloadLoading ...

A Novel Urine DNA Predictor for Noninvasive Early Diagnosis and Monitoring Minimal Residual Disease of Upper Tract Urothelial Carcinoma

PD46-04 A NOVEL URINE DNA PREDICTOR FOR NONINVASIVE EARLY DIAGNOSIS AND MONITORING MINIMAL RESIDUAL DISEASE OF UPPER TRACT UROTHELIAL CARCINOMA

Letter to the Editor: clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinoma

Noninvasive early detection and recurrence monitoring for non-muscle-invasive bladder cancer via urine tumor DNA.

2399P Circulating Tumor DNA and Urine Tumor DNA Detection of Minimal Residual Disease in Upper Tract Urothelial Carcinoma with Radical Nephroureterectomy: A Cohort Study

Novel Use of Ctdna to Identify Muscle-Invasive and Non-Organ-confined Upper Tract Urothelial Carcinoma.

Microfluidic Assaying of Circulating Tumor Cells and Its Application in Risk Stratification of Urothelial Bladder Cancer

Cell-free urinary tumor DNA to detect minimal residual disease prior to repeat-transurethral resection of bladder tumor in non–muscle-invasive bladder cancer: A prospective study.

Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial

Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer

Large-scale Prospective Validation Study of a Multiplex RNA Urine Test for Noninvasive Detection of Upper Tract Urothelial Carcinoma

Abstract LB105: Sensitive urothelial cancer detection via high volume urine DNA analysis

A Urine-Based Liquid Biopsy Method for Detection of Upper Tract Urinary Carcinoma

Superior Molecular Pathology of Urothelial Bladder Cancer Using Urinary Cell-Free DNA.

UCseek: Ultrasensitive Early Detection and Recurrence Monitoring of Urothelial Carcinoma by Shallow-Depth Genome-Wide Bisulfite Sequencing of Urinary Sediment DNA

Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients

2401P Detection of Molecular Recurrence in Early-Stage Bladder Cancer Patients Using a Urinary Tumor DNA Assay after Transurethral Resection of Bladder Tumor (TURBT)

Urothelial Carcinoma Detection Based on Copy Number Profiles of Urinary Cell-Free DNA by Shallow Whole-Genome Sequencing.

A urine-based liquid biopsy for detection of upper tract urothelial carcinoma: a self-matched study

A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer

PD48-06 URINE CELLULAR DNA METHYLATION AND MUTATION TEST FOR DETECTING UROTHELIAL CARCINOMA